Introduction {#Sec1}
============

The discovery of pulmonary vein (PV) tachyarrhythmias as focal triggers of atrial fibrillation (AF) in many patients resulted in catheter ablation as a treatment modality for AF \[[@CR1]\]. AF initiation and maintenance has also been attributed in some patients to non-PV sites like the posterior left atrial (LA) wall, ligament of Marshall, superior vena cava, coronary sinus \[[@CR2]\], vagally mediated LA ganglionated plexi (GP) \[[@CR3], [@CR4]\], and areas of complex fractionated atrial electrograms (CFAE) \[[@CR5]\] and rotors \[[@CR6]\]. Despite the recognized contribution of non-PV drivers to the initiation and maintenance of AF, PV isolation remains the gold standard for ablation aimed at eliminating symptomatic AF \[[@CR7]\]. Studies reporting ablation outcomes show that persistent or long-standing persistent AF, LA size, and the presence of hypertension, diabetes, coronary artery disease, and non-PV triggers decrease the success of AF ablation \[[@CR8]--[@CR16]\]. Single procedures do not always eliminate AF and repeat ablations are an important part of the AF ablation strategy \[[@CR8]\]. Despite these advances, many patients undergo AF ablation without elimination of their AF \[[@CR17]\]. The present study examines a single center's experience with AF ablation and our changes over time in patient demographics, outcomes of initial and final ablations, procedural variables, and complications. These temporal trends provide insights into the evolution of AF ablation and suggest that ablationists may need a better understanding of individual patients AF mechanisms to further improve AF ablation outcomes.

Methods {#Sec2}
=======

Patient population {#Sec3}
------------------

The subjects were consecutive symptomatic patients undergoing AF ablation at Sequoia Hospital, Redwood City, CA, USA from October 10, 2003 to December 31, 2010. All signed written informed consent. Data collection was prospective and approved by the hospital IRB. AF type was categorized as paroxysmal (AF1: lasting \<1 week), persistent (AF2: lasting \>1 week and \<1 year or requiring pharmacological or electrical cardioversion in \<1 week), and long-standing persistent (AF3: lasting \>1 year) \[[@CR7]\].

Ablation protocol {#Sec4}
-----------------

Our ablation protocol \[[@CR8]\] and anticoagulation strategy \[[@CR18]\] have been previously published, and some of the patients in this study were included in previous publications \[[@CR8], [@CR19]\]. Antiarrhythmic drugs (AADs) were stopped ≥5 half-lives and amiodarone ≥3 months before ablation. General anesthesia and right groin venous access were used in most ablations. A 7 F duodecapolar catheter (St. Jude (St. Paul, MN, USA) Livewire^TM^) was placed around the tricuspid valve annulus with the distal poles in the coronary sinus. A 9 F Boston Scientific (Natick, MA, USA) Ultra Ice^TM^ catheter guided the transseptal puncture, done using a 71-cm St. Jude BRK^TM^ or Baylis (Montreal, QC, Canada) NRG^TM^ needle \[[@CR20]\]. Patients had a femoral or radial arterial line. The St. Jude NavX^TM^ system was used in all cases. Prior to January 2006, we used a closed tip catheter (Boston Scientific Blazer II^TM^ or Webster (Diamond Bar, CA, USA) Celsius^TM^ 8 mm) and, thereafter, an open irrigated tip catheter (Webster Thermocool^TM^ 3.5 mm or St. Jude Cool Path^TM^ or Sapphire-Blu^TM^ 4.0 mm). Most irrigated tip catheter ablations were done using 50 W and the technique of "perpetual motion" where the catheter is moved back and forth across a small area and not left at single sites for extended times \[[@CR21]\]. All patients underwent circumferential atrial ablation around all PVs and a LA roof-line ablation. Only patients with right or LA isthmus flutter underwent a caval-tricuspid or mitral isthmus linear ablation. Many patients had low posterior LA lines and those with LA CFAE had them ablated. Some patients underwent ablation in the coronary sinus (at 30--35 W) and/or superior vena cava isolation. After wide area ablation around all veins, a circumferential mapping catheter (7 F Webster Lasso^TM^ or St. Jude Reflexion Spiral^TM^) was used to isolate all PVs defined as complete local electrical silence indicating entrance block. After May 2010, all patients underwent pacing from the PVs to document exit block. NavX^TM^ activation and entrainment mapping were used to ablate flutters and tachycardias. Isoproterenol was given and non-PV triggers were mapped and ablated.

Anticoagulation {#Sec5}
---------------

Patients receiving warfarin continued it until 5 days pre-procedure. Three days pre-procedure, they began enoxaparin 1 mg/kg every 12 h with the last dose 24 h pre-ablation. Patients with AF2, AF3, or frequent AF1 underwent transesophageal echocardiogram. When the transseptal sheath entered the LA, we gave a heparin bolus followed by a 1,000-U/h infusion through the transseptal sheath adjusted by the activated clotting time (ACT). The initial target ACT was \>300--350 s, reduced to 225 after the irrigated tip catheter was introduced \[[@CR18]\]. Post-ablation, we used enoxaparin 0.5 mg/kg q12h until warfarin (continued ≥3 months) achieved an international normalized ratio (INR) of 2.0--3.0. After November 2010, some patients received dabigatran following ablation \[[@CR22]\].

Data collection and analysis {#Sec6}
----------------------------

For each patient, we recorded age, gender, AF duration and type, number of antiarrhythmic drugs failed, CHADS~2~ score, body mass index (BMI), strokes/transient ischemic attacks (TIAs), LA size, prior cardioversions, and comorbidities including hypertension, diabetes, coronary artery disease, and cardiomyopathy. For each ablation, we recorded average ACT, fluoroscopy, and procedure time. Procedural data were evaluated by ablation year for all initial and repeat ablations combined. For all patients of each AF type, outcome was determined after the initial ablation by year of procedure and after the final ablation by year of procedure. Due to the small number of patients, years 2003 and 2004 were combined.

Complications {#Sec7}
-------------

Complications were categorized as major or minor by the year of ablation for the combined initial and repeat ablations. Major complications included death, pericardial tamponade, stroke, atrio-esophageal fistula, PV stenosis \>50% requiring intervention, groin complications requiring surgery or transfusion, heart block, severe tongue hematoma due to intubation, and severe protamine reaction. Minor complications included transient cough, elective late pericardiocentesis, groin complications treated with a minor procedure, esophageal irritation requiring no intervention, PV stenosis \>50% not requiring intervention, pacer lead dislodgement, TIA, urethral trauma, urinary tract infection, mild tongue hematoma due to intubation, and pneumonia.

Follow-up {#Sec8}
---------

Many patients were treated with AADs during the 3-month blanking period post-ablation. Patients transmitted daily electrocardiogram (ECG) strips for 1--3 months post-ablation and were seen at 3 months when an echocardiogram and ambulatory ECG monitor for ≥24 h were performed. Initial ablation failures, defined as recurrent AF, tachycardia, or flutter lasting \>30 s off of drugs ≥3 months post-procedure, were encouraged to undergo a repeat ablation. Patients were seen or contacted frequently from 3--12 months and came for a 1-year follow-up with echocardiogram and 24-h ECG. Thereafter, every 6--12 months, patients were seen directly or contacted via telephone by research nurses or the attending physician, and arrhythmia records were obtained from hospitals and referring physicians. Patients were advised to call for arrhythmia symptoms and ECG recorders were reissued to them. During 2011, all patients considered AF-free \>1 year post final ablation were encouraged to undergo a 1-week continuous monitor. Late pacemaker AF data were utilized when available. One patient was lost to follow-up.

Statistical analysis {#Sec9}
--------------------

Statistical analysis was done using XLSTAT 2010 (Paris, France). Continuous data were described as mean ± standard deviation and categorical data as counts and percentages. Analysis of variance and the Cochran--Armitage trend analysis were used to compare procedural variables including average ACT, procedure and fluoroscopy times, and complications, as well as clinical parameters including age, gender, BMI, AF duration and type, number of AADs failed, prior cardioversions, LA size, CHADS~2~ score, and the presence of coronary artery disease, dilated cardiomyopathy, hypertension, and prior stoke/TIA among patients grouped by year of initial ablation. Kaplan--Meier curves were generated for AF-free survival by AF type and by ablation year for the initial ablation and for final outcome by the year of the last ablation. All tests were two-sided and *P* \< 0.05 was considered statistically significant.

Results {#Sec10}
=======

Patient population {#Sec11}
------------------

The subjects were 1,125 consecutive patients who underwent 1,504 ablations for symptomatic AF. Table [1](#Tab1){ref-type="table"} shows the patient characteristics by year of initial ablation. The number of initial ablations increased from 40 to 280 from 2003 to 2010. The total number of ablations/year increased from 43 to 380. There was a gradual increase in age from 59.0 ± 11.1 to 64.3 ± 10.0 years (*P* \< 0.0001) and an increase in the average CHADS~2~ score from 0.77 ± 0.95 to 1.15 ± 1.08 (*P* \< 0.0001). Over time, more patients had comorbidities including hypertension (*P* \< 0.0001), coronary artery disease (*P* \< 0.021) and prior strokes/TIAs (*P* = 0.005). Although there were more repeat ablations (*P* = 0.036) over time, this largely resulted from the fact that in the early years of our AF ablation program, there were only initial ablations. From approximately 2007 to 2010, the percentage of repeat ablations remained stable at 26%. There was no change in gender, number of AADs failed, duration of AF prior to ablation, BMI, or LA size over time.Table 1Clinical characteristics by year of initial ablation2003--2004200520062007200820092010*P* valueInitial ablations4065133170196241280NARepeat ablations3 (7.0%)14 (17.7%)43 (24.4%)63 (27.0%)71 (26.6%)85 (26.1%)100 (26.3%)=0.036\*Total ablations4279176233267326380NAAge (years)59.0 ± 11.158.4 ± 10.561.6 ± 9.961.4 ± 10.662.1 ± 10.362.8 ± 10.064.3 ± 10.0\<0.0001\*Gender (% female)35.0%23.1%23.3%30.6%25.5%30.3%31.8%=0.202Duration of AF (years)5.6 ± 5.37.9 ± 8.06.9 ± 6.86.6 ± 7.85.9 ± 6.26.7 ± 7.86.0 ± 6.5=0.336\# Drugs failed1.55 ± 0.961.58 ± 1.011.41 ± 1.181.22 ± 1.001.15 ± 0.971.25 ± 0.981.34 ± 1.14=0.336Average CHADS~2~ score0.77 ± 0.950.58 ± 0.880.78 ± 0.830.70 ± 0.880.78 ± 0.970.91 ± 0.941.15 ± 1.08\<0.0001\*Body mass index28.1 ± 4.329.2 ± 5.529.5 ± 5.429.5 ± 5.429.3 ± 5.129.5 ± 5.429.9 ± 5.6=0.601LA size (cm)4.13 ± 0.774.36 ± 0.664.37 ± 0.624.38 ± 0.674.31 ± 0.714.26 ± 0.674.29 ± 0.72=0.308Hypertension45.0%24.6%40.6%38.8%46.4%49.0%57.9%\<0.0001\*Diabetes10.0%13.8%6.8%7.1%8.2%5.8%12.9%=0.458Cardiomyopathy2.5%13.3%10.5%9.4%5.1%7.1%8.9%=0.710Coronary artery disease7.5%10.8%8.3%11.8%15.3%15.5%15.0%=0.021\*Prior cardioversion45.0%44.6%44.4%47.6%46.4%46.3%48.6%=0.415Prior stroke/TIA2.5%1.5%8.3%3.5%6.1%7.1%8.9%=0.005\**AF* atrial fibrillation, *TIA* transient ischemic attack, *NA* not applicable\**P* \< 0.05

There was a gradual change in the composition of patients referred for AF ablation by AF type (Fig. [1](#Fig1){ref-type="fig"}). There was a slight decrease in the number of patients with AF1 which did not reach statistical significance (*P* = 0.07), a decline in the number with AF3 (*P* \< 0.001) and an increase in the number with AF2 (*P* \< 0.0001).Fig. 1Percentage of AF patients with each type of AF (*green* = paroxysmal AF1, *blue* = persistent AF2, and *black* = long-standing persistent AF3) by year of initial ablation

Procedural variables {#Sec12}
--------------------

Figure [2](#Fig2){ref-type="fig"} shows the average procedural and fluoroscopy times for the combination of initial and repeat ablations by year. From 2003--2004 to 2010, there was a significant shortening of procedure times from 256 ± 49 to 122 ± 28 min (*P* \< 0.0005) and fluoroscopy times from 134 ± 29 to 56 ± 9 min (*P* \< 0.0005). Figure [3](#Fig3){ref-type="fig"} shows the decrease in ACT (from 338 ± 30 to 229 ± 21 s, *P* \< 0.0001) over time.Fig. 2Changes in procedure and fluoroscopy time (*green* = procedure time, *blue* = fluoroscopy time) by year of initial ablationFig. 3Decline in average procedural ACT by year

Outcomes by year {#Sec13}
----------------

Figure [4](#Fig4){ref-type="fig"} shows the Kaplan--Meier curves for freedom from AF after initial ablation by year and AF type. Figure [4(A)](#Fig4){ref-type="fig"} shows a statistically significant year-to-year improvement in outcomes after the initial ablation for AF1 patients (*P* = 0.015). Despite the overall improvement, inspection of the Kaplan--Meier curves shows little improvement after 2006. Figure [4(B)](#Fig4){ref-type="fig"} shows a trend towards year-to-year improvement in initial ablation outcomes for AF2 patients (*P* = 0.062) with no improvement after 2007. Figure [4(C)](#Fig4){ref-type="fig"} shows year-to-year initial ablation outcomes for AF3 patients and demonstrates no improvement over the years (*P* = 0.995).Fig. 4Kaplan--Meier curves for freedom from AF after initial AF ablation by year ((**A**) paroxysmal AF1, (**B**) persistent AF2, (**C**) long-standing persistent AF3). *Blue* = 2003--2004, *purple* = 2005, *red* = 2006, *green* = 2007, *black* = 2008, *gray* = 2009, *yellow* = 2010

Figure [5](#Fig5){ref-type="fig"} shows the Kaplan--Meier curves for the outcome after the final ablation (average of 1.34 ablations/patient) by year of last ablation. Figure [5](#Fig5){ref-type="fig"}(A--C) shows that there was no improvement over time for the final outcome in patients with AF1 (*P* = 0.325), AF2 (*P* = 0.150), or AF3 (*P* = 0.978). For both AF1 and AF2, the rates of freedom from AF after the final ablation for 2010 may be artificially low due to the fact that many of these patients have only undergone an initial ablation.Fig. 5Kaplan--Meier curves for freedom from AF after the last AF ablation by year of last ablation. (**A**) Paroxysmal AF1, (**B**) persistent AF2, (**C**) long-standing persistent AF3. Color code the same as Fig. [4](#Fig4){ref-type="fig"}

Procedural complications {#Sec14}
------------------------

Figure [6](#Fig6){ref-type="fig"} shows the trend over time for procedural complications for the combination of initial and repeat ablations by year. Major procedural complications have decreased gradually from 4.65% of ablations in 2003--2004 to 0.53% in 2010 (*P* = 0.023). Minor complications also decreased over time from 4.65% in 2003 and 2004 to 1.05% in 2010 (*P* = 0.023). The combined total of major and minor complications decreased from 9.30% to 1.58% over time (*P* = 0.001). The shape of the curve indicates a long learning curve of about 6 years to minimize ablation complications. All individual major and minor complications over time are shown in Table [2](#Tab2){ref-type="table"}. There were no deaths, atrio-esophageal fistulae, or PV stenoses requiring intervention. Although the total number of complications decreased over time, the incidence of pericardial tamponade was the only individual complication to decrease over time (*P* = 0.02).Fig. 6Percent of AF ablations with major (*red*) and minor (*blue*) complications by year. The *black line* represents the total complications (major + minor) by yearTable 2Complications by year of initial ablation2003--2004200520062007200820092010*P* valueTotal ablations4379176233267326380NACough which resolved0 (0.0%)0 (0.0%)0 (0.0%)1 (0.4%)2 (0.7%)0 (0.0%)1 (0.3%)=0.22Groin complications (major + minor)0 (0.0%)1 (1.3%)4 (2.3%)1 (0.4%)6 (2.2%)1 (0.3%)1 (0.3%)=0.11Esophageal irritation0 (0.0%)0 (0.0%)1 (0.6%)0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)=0.22PV stenosis \>50% no intervention0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)1 (0.4%)0 (0.0%)0 (0.0%)=0.97Pacer lead dislodgment0 (0.0%)0 (0.0%)1 (0.6%)0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)=0.22Urethral trauma0 (0.0%)0 (0.0%)0 (0.0%)1 (1.3%)0 (0.0%)0 (0.0%)0 (0.0%)=0.52Severe urinary infection0 (0.0%)1 (1.3%)0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)=0.07Pneumonia1 (2.3%)0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)1 (0.3%)0 (0.0%)=0.19Eye keratopathy, transient0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)1 (0.3%)=0.25Tongue hematoma (major + minor)0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)2 (0.5%)=0.10Elective, non-tamponade pericaridocentesis0 (0.0%)1 (1.3%)0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)0.07Pericardial tamponade1 (2.3%)1 (1.3%)1 (0.6%)3 (1.3%)2 (0.7%)1 (0.3%)0 (0.0%)=0.02^a^Stroke/TIA2 (4.7%)0 (0.0%)0 (0.0%)0 (0.0%)1 (0.4%)1 (0.3%)1 (0.3%)=0.15Severe protamine reaction0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)1 (0.4%)0 (0.0%)0 (0.0%)=0.97Heart block0 (0.0%)0 (0.0%)0 (0.0%)1 (0.4%)0 (0.0%)0 (0.0%)0 (0.0%)=0.52Total4 (9.3%)4 (5.1%)7 (4.0%)7 (3.0%)13 (4.9%)4 (1.2%)6 (1.6%)=0.001^a^*TIA* transient ischemic attack, *NA* not applicable^a^Statistically significant

Discussion {#Sec15}
==========

This study reveals two key trends that occurred over time at our institution: (1) the clinical characteristics of patients undergoing AF ablation changed and (2) post-procedure outcomes did not improve commensurate with improvements in procedural performance. From 2003 to 2010, there was a gradual change in the baseline demographics of patients undergoing AF ablation. Patients are now older with higher CHADS~2~ scores and more persistent AF. The recognition of these trends is critical because of the key role that clinical factors play in determining AF ablation efficacy. The fact that LA size, duration of AF, number of AADs failed and prior cardioversions did not change over time suggests that patients are not being referred for ablation earlier in their disease process. The outcomes of AF ablation might be improved by earlier referral.

Despite optimization of procedural factors, i.e., performing AF ablations faster and with fewer complications, our outcomes after the initial and final ablation have either not improved or have plateaued. Improvements in outcomes for initial ablations over time were greatest for AF1 and least for AF3. However, even for AF1, ablation outcomes seem to have reached a ceiling several years ago. Although we appear to have optimized our AF-free rates after a few years of ablation experience, it took approximately 6 years and almost 800 ablations for the complication rates to reach a nadir. This suggests that the learning curve for performing ablations safely is not insignificant even in the hands of experienced ablationists. Part of our reduction in complications may be due to operator experience; however, part is due to procedural changes such as using only one groin for all venous access and the use of the radiofrequency transseptal needle which we have shown to reduce the incidence of pericardial tamponade \[[@CR20]\]. While we recognize that most centers keep their target ACT \>300--350 s, we have found that lowering our target ACT level reduced our overall vascular and hemorrhagic complication rate \[[@CR18]\]. It is important to emphasize that when keeping the target ACT lower, one must use only a single transseptal puncture and should infuse maintenance heparin through the transseptal sheath. The change to general anesthesia \[[@CR23]\] and the use of the irrigated tip ablation catheter at 50 W \[[@CR21]\] early in our ablation series may also have contributed to procedural improvements over time. Many centers now perform AF ablation on patients with a therapeutic INR. However, it is becoming more difficult to do uninterrupted oral anticoagulation as more patients are referred for ablation on the direct thrombin inhibitor, dabigitran, which has no reversal agent, making it potentially dangerous to perform a procedure on a fully orally anticoagulated patient \[[@CR22]\].

Lemola et al. \[[@CR24]\] showed that when an initial ablation has failed, repeat electroanatomic mapping shows that ≥1 PVs have reconnected in 98% of patients. PV reconnection is not necessarily, however, the only cause of ablation failure. It is also possible that even if we can permanently eliminate all existing PV--LA connections with a single procedure, new connections may regenerate *de novo* over time. Studies have shown that PV isolation is not necessarily needed to eliminate AF \[[@CR25]\]; for example, ablation of CFAEs or left atrial GP can eliminate AF in some patients \[[@CR3]--[@CR5]\]. In a randomized trial of AF1 patients, Katritsis et al. \[[@CR3]\] reported that 45.5% were AF-free with PV isolation alone compared with 73.5% with PV isolation plus GP ablation at 4.7 months post-ablation. In our series, the wide area circles we ablate around all veins prior to using a circular catheter to finish vein isolation encompass the major anatomical locations of GP, probably accomplishing both PV isolation and GP ablation. Our AF-free rate after a single ablation is virtually identical to those of Katritsis et al. \[[@CR3]\] in patients who received both PV isolation and GP ablation. The role of rotors and CFAEs in AF ablation remains incompletely understood. Preliminary evidence suggests that ablating rotors may also alleviate AF \[[@CR6]\].

Our data also suggest that one cannot use long-term outcomes from patients with paroxysmal AF ablations years ago to judge the efficacy of contemporary ablations. Weerasooriya et al. \[[@CR26]\] reported only a 40% long-term success rate after a single procedure done in Bordeaux, France in 2001--2002. A more contemporary series from that center reported a 1-year AF-free rate of 61.8% after a single procedure \[[@CR27]\].

Many of the new AF ablation technologies may not be able to significantly improve AF ablation results. Robotic \[[@CR28]\] and magnetic navigation systems \[[@CR27]\] do the job that ablationists do manually with a different technology but do not contribute to a better understanding of *what we should be ablating*. Although it is theoretically possible that better tissue contact with a robotic system could result in better ablation outcomes, early results do not suggest this is the case. In a study randomizing patients to manual catheter manipulation vs. magnetically controlled ablation, there was no difference in outcome and patient radiation exposure and procedure time increased with the magnetic navigation system \[[@CR27]\]. Other technologies holding promise for improved PV isolation have not yet demonstrated improved outcomes. The cryoballoon is another promising new technology for AF ablation. A recent literature review of the efficacy of this technology showed a single procedure 1-year AF-free rate of 69.9% to 76.7% for paroxysmal AF and 41.9% to 48.4% for persistent AF \[[@CR29]\]. These numbers do not suggest that the cryoballoon will dramatically increase the success of AF ablation. In this era of economic constraints, new technologies must be evaluated carefully for contributions to impoved safety and/or efficacy of AF ablation as virtually all increase procedural costs.

AF ablation improves the quality of life in a high percentage of patients undergoing the procedure. Although AF ablation currently has a high rate of success \[[@CR9]--[@CR16]\], it would be desirable to eliminate AF in an even greater number of patients and to decrease the need for repeat ablations \[[@CR8]\]. In order to incrementally improve ablation outcomes, we need a better understanding of AF. The diversity of potential AF mechanisms and our lack of understanding of how AF occurs in individual patients are summarized in an editorial by Katritsis and Camm \[[@CR30]\]. We need new and improved methods to identify the exact AF triggers and perpetuators *in each patient*. For example, it might be useful to have ambulatory body surface mapping to document the site of origin of AF in ambulatory patients prior to ablation.This might allow us to target a particular PV or a non-PV trigger causing AF in an individual patient with less widespread ablation. We might also discover that individual patients have multiple initiators and that the mechanism of AF can change over time. It is likely that the best immediately available technique for improving ablation outcome is for patients to have ablation earlier in the disease process before they develop LA dilatation, fail numerous AADs \[[@CR31]\], and progress from AF1 to AF2 or AF3.

Limitations {#Sec16}
-----------

Our data are from a single referral center case series which has inherent limitations including patient selection and referral bias. It is difficult to determine how much of our temporal reduction in complications was due to improved operator skill vs. procedural modifications over time, such as lowering our target ACT \[[@CR18]\] or utilizing the RF transseptal needle \[[@CR20]\]. As in all long-term follow-up studies, the ability to monitor patients decreased over time and we could have missed asymptomatic AF despite our regular follow-up and frequent contact by trained research personnel. Despite its shortcomings, our method of long-term follow-up is essentially the same as that used by most other referral centers reporting on long-term outcomes of AF ablations \[[@CR11], [@CR12], [@CR26], [@CR32]\]. Any missed asymptomatic AF should have occurred equally across all years and is not likely to have changed the conclusions of our study.

Conclusions {#Sec17}
===========

The AF ablation procedure has progressed over the last decade and, based on our experience, can be done increasingly faster and more safely, with shorter fluoroscopy and procedure times than at its inception. Despite these procedural advances, AF ablation appears to have plateaued with regard to our ability to eliminate AF in a higher percentage of patients. New technologies such as robotic and magnetic navigation systems and cryoballoon ablation systems do not seem to dramatically improve current ablation outcomes, as they only allow us to do what we are already doing with a different tool, rather than help us decide what we should be ablating in each individual patient. Breaking through the ceiling on AF ablation efficacy that we reached several years ago will probably require improved understanding of the mechanism of AF initiation and maintenance in individual patients in order to personalize ablation protocols to each patient's needs. The precise pathway to this new paradigm is a bit unclear but perhaps new technology that reveals the mechanisms of AF rather than technology designed to ablate AF might lead us there more rapidly.
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